LOUISVILLE, KY - Humana Inc . (NYSE:HUM), a $31.9 billion healthcare provider with strong financial health according to InvestingPro metrics, held its annual shareholder meeting on Thursday, where all eleven director nominees were elected and PricewaterhouseCoopers LLP was ratified as the company’s independent auditor for the current fiscal year.
During the meeting, which took place on April 17, 2025, shareholders present by proxy voted on three proposals outlined in the company’s proxy statement. A total of 105,203,172 shares were represented at the meeting, providing the necessary quorum.
The first proposal involved the election of the board of directors, with each nominee securing their position for a term lasting until the next annual meeting. The elected board members include Raquel C. Bono, M.D., Frank A. D’Amelio, David T. Feinberg, M.D., Wayne A. I. Frederick, M.D., John W. Garratt, Kurt J. Hilzinger, Karen W. Katz, Marcy S. Klevorn, Jorge S. Mesquita, James A. Rechtin, and Gordon Smith. The vote counts ranged from 93,912,129 in favor for Karen W. Katz to 99,603,400 for Raquel C. Bono, M.D., with abstentions and broker non-votes also recorded.
The second proposal, which passed with 98,877,049 votes in favor, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for Humana for the year ending December 31, 2025.
Lastly, the non-binding advisory vote on the company’s executive compensation received approval, with 89,310,631 votes for, 10,567,799 against, and 131,538 abstentions.
These results reflect the shareholders’ support for the company’s current leadership and financial oversight practices. The election of the board members and the ratification of the accounting firm are part of Humana’s annual governance process. The company’s management has demonstrated confidence through aggressive share buybacks, while maintaining a healthy current ratio of 1.76 and generating $117.8 billion in revenue. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report covering this prominent healthcare provider.
The information is based on a press release statement filed with the SEC. Investors should note that Humana’s next earnings report is scheduled for April 30, 2025. For detailed financial analysis and more exclusive insights, including 8 additional ProTips, visit InvestingPro.
In other recent news, Humana Inc. has been in the spotlight due to several significant developments impacting the company. UnitedHealth Group (NYSE:UNH)’s unexpected downward revision of its earnings forecast, citing higher-than-anticipated medical costs in Medicare, has caused a ripple effect throughout the health insurance sector. This announcement led to a sharp decline in Humana’s shares, as well as those of other major health insurers. In a separate development, Guggenheim has initiated coverage on Humana with a Buy rating and a price target of $326, citing the company’s strong position in the Medicare sector despite upcoming challenges.
Meanwhile, Cantor Fitzgerald has reiterated a Neutral rating on Humana, maintaining a price target of $290. The firm expressed a cautious outlook, emphasizing potential uncertainties related to Humana’s ongoing legal challenges and the 2027 STARS ratings. Additionally, the Centers for Medicare and Medicaid Services announced a substantial 5.06% increase in Medicare insurer payment rates for 2026, which has positively impacted Humana and other healthcare insurers. This increase, more than double the initial proposal, is expected to generate significant additional revenue for the industry.
These recent developments underscore the complex landscape Humana navigates, with both opportunities and challenges shaping its future trajectory. Investors are closely monitoring the company’s strategic decisions and legal proceedings, which could significantly influence its operational performance and shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.